InFo Hämatologie + Onkologie, Год журнала: 2024, Номер 27(12), С. 30 - 31
Опубликована: Дек. 1, 2024
Romanian Journal of Morphology and Embryology, Год журнала: 2025, Номер 65(4), С. 627 - 635
Опубликована: Фев. 13, 2025
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic worldwide and has become a major public health problem. MASLD frequently progresses to cirrhosis hepatocellular carcinoma, but recent studies also show frequent association with extrahepatic cancers. One of mechanisms involved in both locations insulin resistance hyperinsulinemia. The aim this narrative review was present main etiopathogenic cancer development patients MASLD.
Язык: Английский
Процитировано
0
Current Issues in Molecular Biology, Год журнала: 2024, Номер 46(9), С. 9721 - 9759
Опубликована: Сен. 2, 2024
Somatostatin is a peptide that plays variety of roles such as neurotransmitter and endocrine regulator; its actions cell regulator in various tissues the human body are represented mainly by inhibitory effects, it shows potent activity despite physiological low concentrations. binds to specific receptors, called somatostatin receptors (SSTRs), which have different tissue distributions associated signaling pathways. The expression SSTRs can be altered conditions, including tumors; therefore, they used biomarkers for cancer susceptibility certain pharmacological agents provide prognostic information regarding disease evolution. Moreover, based on affinity analogs types SSTRs, therapeutic range includes conditions tumors, acromegaly, post-prandial hypotension, hyperinsulinism, many more. On other hand, number antagonists may prove useful medical settings, their differential SSTRs. aim this review present detail principal characteristics all five an overview potential neoplasias.
Язык: Английский
Процитировано
1
Diagnostics, Год журнала: 2024, Номер 14(18), С. 2054 - 2054
Опубликована: Сен. 16, 2024
Hepatocellular carcinoma (HCC), the most common primary liver malignancy and sixth cancer globally, remains fatal for many patients with inappropriate responses to treatment. Recent advancements in immunotherapy have transformed treatment landscape advanced HCC. However, variability patient highlights need biomarkers that can predict outcomes. This manuscript comprehensively reviews evolving role of efficacy, spanning from blood-derived indicators—alpha-fetoprotein, inflammatory markers, cytokines, circulating tumor cells, their DNA—to tissue-derived indicators—programmed cell death ligand 1 expression, mutational burden, microsatellite instability, tumor-infiltrating lymphocytes. The current body evidence suggests these hold promise improving selection predicting Each biomarker offers unique insights into disease biology immune HCC, potentially enhancing precision strategies. challenges such as methodological variability, high costs, inconsistent findings, large-scale validation well-powered two-arm trial studies persist, making them currently unsuitable integration standard care. Addressing through standardized techniques implementation further will be critical future incorporation clinical practice
Язык: Английский
Процитировано
0
Gastro-News, Год журнала: 2024, Номер 11(5), С. 16 - 17
Опубликована: Окт. 1, 2024
Процитировано
0
World Journal of Experimental Medicine, Год журнала: 2024, Номер 14(4)
Опубликована: Окт. 29, 2024
BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic with significant risk developing hepatocellular carcinoma (HCC). Recent clinical evidence indicates the potential benefits statins in cancer chemoprevention and therapeutics. However, it still unclear if can lower specific HCC among patients MASLD. AIM To investigate impact statin use on development METHODS A systematic review meta-analysis all studies was performed that measured effect occurrence The difference between users non-users calculated MASLD patients. We also evaluated lipophilic versus hydrophilic cumulative dose reduction. RESULTS total four consisting 291684 were included. therapy had 60% pooled compared to non-statin group [relative (RR) = 0.40, 95%CI: 0.31-0.53, I2 16.5%]. Patients taking reduced (RR 0.42, 0.28-0.64), whereas those not shown reduction 0.57, 0.27-1.20). higher (> 600) defined daily doses (cDDD) 70% 0.30, 0.21-0.43). There 29% 0.71, 0.55-0.91) 43% 0.40-0.82) decreased receiving 300-599 cDDD 30-299 cDDD, respectively. CONCLUSION Statin lowers lipophilicity correlate
Язык: Английский
Процитировано
0
InFo Hämatologie + Onkologie, Год журнала: 2024, Номер 27(12), С. 30 - 31
Опубликована: Дек. 1, 2024
Процитировано
0